Development of the prototype of new universal Hepatitis B recombinant vaccine
Project is being carried out within the ERDF 220.127.116.11. activity „Support for Science and Research”
Project agreement Nr. 2010/0211/2DP/18.104.22.168.0/10/APIA/VIAA/048
Project duration: 36 months (01.10.2010.-30.09.2013.)
Project costs: 369872 LVL
Principal investigator: Dr. biol. Andris Dišlers
Specific aim of the project
Development of new Hepatitis B vaccine prototype on the basis of HBV core-antigen HBcAg and preS1, and technology for production of recombinant HBcAg-preS1 virus-like particles (VLPs) with high purity standard.
Activities implemented during the project:
1. Industrial research - development of new product – prototype of universal Hepatitis B vaccine.
1.1. Design of HBcAg-preS1 expression vectors, construction and selection of optimal variants.
1.2. Research to find the principles of chimeric HBcAg-preS1 VLP purification.
1.3. Immunological testing of vaccine prototype.
1.4. Test of virus-neutralising activity of HBcAg-preS vaccine prototype.
2. Experimental development – technology development for chimeric HBc-preS VLP obtaining
2.1. Producer strain optimization.
2.2. Optimization of cultivation conditions and biomass production.
2.3. Development of purification protocol for chimeric HBcAg-preS1 VLPs.
2.4. End product characterization, validation and formulation of product.
As a result of the project, the following will be developed:
New product: Prototype of universal Hepatitis B virus vaccine
New technology: Technology for chimeric HBc-preS VLP obtaining